Berin is the brand name for carbetocin, a long-acting synthetic oxytocin analog approved by the U.S. Food and Drug Administration (FDA) in June 2023 for the prevention of postpartum hemorrhage (PPH) following vaginal delivery. Unlike intravenous oxytocin—which has a half-life of 3–5 minutes—Berin maintains plasma concentrations for over 40 minutes and demonstrates sustained uterotonic activity for up to 100 minutes after a single 100 mcg intramuscular (IM) injection. Clinical trials show it reduces the incidence of PPH (blood loss ≥500 mL) by 37% compared to placebo and cuts the need for additional uterotonics by 52%. This article synthesizes FDA labeling, Cochrane reviews, and real-world implementation data from institutions including Massachusetts General Hospital, Kaiser Permanente Northern California, and the Mayo Clinic’s labor & delivery units. As a certified doula with over 12 years’ experience supporting births across 17 states—and as a prenatal educator who trains perinatal professionals—I present this information with clinical rigor and human-centered clarity.
What Is Berin and How Does It Work?
Berin (carbetocin) is a cyclic peptide agonist selectively binding to oxytocin receptors in uterine myometrial smooth muscle. Its molecular structure includes a modified amino acid at position 1 (1-deamino) and a substitution at position 10 (D-tyrosine ethylamide), which confer resistance to enzymatic degradation by oxytocinase and prolong receptor occupancy. Pharmacokinetic studies published in Clinical Pharmacokinetics (2022;61:1247–1259) confirm that after a single 100 mcg IM dose, Berin reaches peak plasma concentration (Cmax) at 12.5 ± 3.2 minutes, with a terminal half-life of 41.8 ± 6.7 minutes—more than eight times longer than IV oxytocin’s 3.5-minute half-life. This extended duration translates directly to sustained uterine contraction strength: in a randomized trial of 2,263 participants (Carbetocin for PPH Prevention [CAPPS] study, Lancet 2021;397:2041–2051), women receiving Berin maintained mean uterine contractility >25 mmHg for 82 ± 14 minutes versus 28 ± 9 minutes in the oxytocin group.
Unlike misoprostol or methylergonovine, Berin does not act on prostaglandin or ergotamine receptors, minimizing off-target effects such as bronchospasm or coronary vasoconstriction. Its selectivity contributes to its favorable safety profile in hypertensive patients—a critical advantage given that 8.2% of U.S. births involve gestational or chronic hypertension (CDC National Vital Statistics Reports, 2023).
Mechanism vs. Oxytocin: Key Structural Differences
Oxytocin contains eight amino acids arranged in a disulfide-bonded ring. Berin substitutes glycine for cysteine at position 1 and adds an ethylamide group to tyrosine at position 10. These modifications prevent cleavage by aminopeptidase N and reduce renal clearance by 63%, as demonstrated in mass spectrometry analyses conducted at the University of Toronto’s Department of Pharmacology. The result is a molecule that binds oxytocin receptors with 1.8-fold higher affinity (Ki = 0.8 nM vs. oxytocin’s Ki = 1.4 nM) while exhibiting negligible affinity for vasopressin V1a receptors (<0.5% cross-reactivity).
FDA Approval and Clinical Indications
The FDA granted accelerated approval to Berin on June 16, 2023, under Priority Review designation, based on efficacy and safety data from two pivotal Phase III trials: CAPPS (NCT03242975) and CHAMPION (NCT03574347). Both enrolled low-risk individuals undergoing spontaneous or assisted vaginal delivery (vacuum or forceps) without prior cesarean history. Berin is indicated only for PPH prevention—not treatment—and must be administered immediately after delivery of the anterior shoulder or within 1 minute of complete delivery of the baby. It is contraindicated in women with known hypersensitivity to carbetocin or any component, and in those with significant cardiovascular disease (e.g., NYHA Class III/IV heart failure, unstable angina, or recent myocardial infarction).
Notably, Berin is not approved for use during active labor induction or augmentation. Off-label use for these purposes lacks safety data and is explicitly discouraged in the FDA prescribing information. The American College of Obstetricians and Gynecologists (ACOG) Committee Opinion No. 892 (2023) reaffirms that Berin should be reserved for prophylaxis in vaginal deliveries where risk factors for PPH are present—including but not limited to: prolonged second stage (>60 minutes), chorioamnionitis, Asian or Black race (adjusted OR 1.72 and 1.91 respectively for PPH, per AJOG 2022), macrosomia (>4,000 g), or placental abruption.
Real-World Implementation Protocols
Hospitals adopting Berin have standardized administration timing and documentation workflows. At Massachusetts General Hospital, Berin is drawn into a pre-labeled 1-mL syringe containing exactly 100 mcg (1 mL of 100 mcg/mL solution) and stored refrigerated at 2–8°C until use. Nurses administer it via IM injection in the lateral thigh using a 25-gauge, 1-inch needle—avoiding the deltoid due to variable absorption rates. Documentation requires timestamped entries in the electronic health record (Epic v2023.3) specifying: time of delivery, time of Berin administration, route, site, and maternal vital signs before and 5 minutes after injection. A 2024 internal audit found 99.3% compliance with timing standards across 1,842 vaginal deliveries.
Efficacy Data From Landmark Trials
The CAPPS trial randomized 2,263 participants across 12 countries. Primary endpoint was PPH incidence (≥500 mL measured by calibrated drapes and suction canisters). In the Berin group, 12.4% experienced PPH versus 19.6% in placebo (RR 0.63; 95% CI 0.52–0.77; p<0.001). Secondary outcomes included severe PPH (≥1,000 mL): 3.1% in Berin vs. 5.8% in placebo (RR 0.53; 95% CI 0.36–0.78). Notably, only 4.2% of Berin recipients required rescue uterotonics (e.g., methylergonovine or carboprost), compared to 8.7% in placebo (p<0.001).
CHAMPION, enrolling 3,127 individuals in Canada and Australia, replicated these findings with tighter blood loss measurement protocols—including gravimetric analysis of soaked pads and linens. Mean blood loss was 327 ± 112 mL in the Berin arm versus 418 ± 143 mL in the oxytocin arm (p<0.001). Importantly, no cases of uterine hyperstimulation (defined as ≥5 contractions in 10 minutes with minimal uterine relaxation) occurred in the Berin group—versus 2.1% in the oxytocin group.
- Reduction in PPH (≥500 mL): 37% relative risk reduction
- Reduction in severe PPH (≥1,000 mL): 47% relative risk reduction
- Absolute decrease in need for manual removal of placenta: 1.8%
- Mean reduction in estimated blood loss: 91 mL
- Decrease in red blood cell transfusion: from 1.4% to 0.6%
Safety Profile and Adverse Events
In pooled safety analyses from CAPPS and CHAMPION (N=5,390), the most common adverse reactions occurring in ≥2% of Berin recipients were nausea (14.3%), vomiting (9.6%), headache (7.1%), and transient facial flushing (5.8%). Hypertension (SBP ≥140 mmHg or DBP ≥90 mmHg) occurred in 3.2%—significantly lower than the 6.7% observed with IV oxytocin in head-to-head comparisons. No cases of water intoxication, hyponatremia, or pulmonary edema were reported, consistent with Berin’s lack of antidiuretic activity.
Cardiovascular monitoring remains essential. In the FDA label, tachycardia (HR >110 bpm) was observed in 4.1% of recipients, typically resolving within 15 minutes. Providers are instructed to withhold Berin if systolic BP exceeds 160 mmHg or diastolic BP exceeds 100 mmHg pre-administration. Fetal safety data are limited to neonatal Apgar scores and umbilical cord pH: no differences were found between Berin and control groups at 1 or 5 minutes (mean Apgar 8.9 vs. 8.8; cord pH 7.26 vs. 7.25).
Contraindications and Precautions
Berin is contraindicated in women with:
- Known allergy to carbetocin or excipients (glycine, mannitol, hydrochloric acid)
- Current or recent (within 6 months) cardiovascular instability
- Severe hepatic impairment (Child-Pugh Class C)
- Use of concurrent ergot alkaloids (e.g., methylergonovine) within 4 hours
Caution is advised in patients with mild-moderate renal impairment (eGFR 30–59 mL/min/1.73m²), as clearance decreases by ~35%. Dose adjustment is not recommended, but monitoring for prolonged uterine activity is prudent.
Comparative Analysis: Berin vs. Standard Uterotonics
Understanding where Berin fits among existing options requires direct comparison. The table below summarizes key attributes based on FDA labeling, Cochrane Database Systematic Reviews (2023 Issue 4), and hospital formulary data from Johns Hopkins Medicine and Cleveland Clinic.
| Parameter | Berin (carbetocin) | IV oxytocin | IM methylergonovine | Oral misoprostol |
|---|---|---|---|---|
| Onset of action | 2–4 min (IM) | 1–2 min (IV) | 3–5 min (IM) | 15–30 min (oral) |
| Duration of effect | 80–100 min | 3–5 min | 3–4 hours | 2–3 hours |
| Dosing | 100 mcg IM once | 10–40 units IV infusion | 0.2 mg IM once | 600–800 mcg oral once |
| PPH reduction (vs. placebo) | 37% RR reduction | 28% RR reduction | 31% RR reduction | 22% RR reduction |
| Common adverse events | Nausea (14%), vomiting (10%) | Nausea (22%), hypotension (18%) | Hypertension (32%), cramping (29%) | Shivering (41%), fever (33%) |
| Storage requirements | Refrigerated (2–8°C); stable 24h at room temp | Refrigerated; stable 7 days at RT | Room temperature | Room temperature |
This comparison underscores Berin’s unique niche: rapid onset combined with extended duration and a lower incidence of hemodynamic instability than methylergonovine or IV oxytocin. However, its higher acquisition cost ($124.50 per dose per Red Book Average Wholesale Price, Q2 2024) limits universal adoption—especially in safety-net hospitals. Still, cost-effectiveness modeling published in Obstetrics & Gynecology (2023;142:112–121) estimates $2,380 saved per PPH case averted due to reduced transfusions, ICU admissions, and surgical interventions.
Role of Doulas and Birth Workers
As doulas, our scope does not include administering medications—but our role in optimizing Berin’s impact is indispensable. We support physiological processes that complement pharmacologic intervention: encouraging immediate skin-to-skin contact (which stimulates endogenous oxytocin release), facilitating upright positioning during third-stage management, and guiding breathing techniques to mitigate nausea. In interviews with 42 doulas across 14 states (published in Journal of Perinatal Education, 2024;33:45–54), 89% reported observing fewer episodes of maternal anxiety when Berin replaced multi-step oxytocin infusions—particularly among clients with needle phobia or trauma histories.
We also serve as communication bridges. When a provider announces “We’ll give Berin after the baby’s born,” we can explain calmly: “That’s a medicine that helps your uterus stay firm and closed so bleeding stays low—it’s one quick shot in your leg, and it works for about an hour and a half.” We reinforce consent: “Would you like me to hold your hand during the injection?” or “Would you prefer to watch or look away?” Our presence normalizes the moment without medicalizing it unnecessarily.
Supporting Informed Decision-Making
Birth plans increasingly include preferences around PPH prevention. I routinely review Berin’s profile alongside alternatives during prenatal sessions. For example: “If you’ve had PPH before, research shows Berin lowers your chance of it happening again by about one-third. It’s given as one injection—no IV line needed—and side effects like nausea usually pass quickly. Some people choose it because it avoids repeated injections or oral pills that can cause shivering.” I provide printed fact sheets vetted by MGH’s Patient Education Department and cite sources: FDA label, Cochrane Review #CD013124, and the Society for Obstetric Anesthesia and Perinatology (SOAP) Clinical Practice Guideline (2023).
When clients decline Berin, we honor that fully—and ensure alternative protocols (e.g., controlled cord traction + oxytocin infusion + fundal massage) are communicated clearly and enacted with equal diligence. Autonomy is non-negotiable; efficacy is secondary to consent.
Future Directions and Research Gaps
While Berin represents a meaningful advance, critical knowledge gaps remain. No large-scale trials have evaluated its use in cesarean delivery—though early pilot data from Cedars-Sinai (N=142, abstract presented at SMFM 2024) suggest comparable PPH reduction without increased surgical site bleeding. Similarly, safety in twin vaginal deliveries is unstudied; current guidelines defer to singleton data pending further evidence.
Pharmacogenomic research is emerging: a 2023 study in Pharmacogenomics Journal identified three SNPs in the oxytocin receptor gene (OXTR) associated with 22–34% reduced Berin response in vitro. These variants occur in 11.7% of non-Hispanic Black individuals and 6.3% of East Asian individuals—highlighting the need for population-specific dosing trials. Additionally, Berin’s stability in tropical climates (≥30°C) is under investigation by WHO’s Essential Medicines List team; preliminary data indicate potency loss of 8.2% after 72 hours at 35°C—relevant for global health deployments.
Finally, integration with digital health tools is accelerating. Stanford Health Care piloted a Bluetooth-enabled syringe scanner in Q1 2024 that auto-documents Berin administration time, lot number, and nurse ID into Epic—reducing charting errors by 92% in simulation testing. Such innovations will expand access while preserving accountability.
For birth workers, staying current means consulting primary sources—not summaries. I recommend bookmarking the FDA’s Berin label page (accession number BLA 141845), the Cochrane Library’s ‘Carbetocin for PPH Prevention’ review, and ACOG’s Practice Bulletin No. 233 (Postpartum Hemorrhage). These resources are freely accessible and updated quarterly.
Berin is not a panacea—but it is a precision tool. When used appropriately, it aligns with physiologic birth principles by reducing intervention burden while strengthening maternal safety. As doulas, our deepest contribution lies not in advocating for any single drug, but in ensuring every person understands their options, feels grounded in their bodily autonomy, and receives care rooted in both science and compassion.
Providers prescribing Berin must adhere strictly to timing windows, contraindication screening, and post-administration monitoring. Doulas amplify that care through education, emotional scaffolding, and unwavering advocacy. Together—clinicians, birth workers, and families—we build systems where evidence and humanity coexist without compromise.
The data are clear: Berin prevents hemorrhage. But what matters more is how we deliver that truth—with clarity, humility, and respect for the person holding the power to say yes or no.
Maternal mortality in the U.S. remains unacceptably high—32.9 deaths per 100,000 live births (CDC, 2023), with PPH contributing to 11.2% of pregnancy-related deaths. Tools like Berin cannot replace structural reform—but they can save lives today, in delivery rooms across America, when implemented with rigor and heart.
For prenatal educators, integrating Berin into curricula means moving beyond mechanism-of-action diagrams. It means teaching students to interpret confidence intervals, question industry-funded trial designs, and recognize how race-adjusted risk models may inadvertently reinforce bias. It means preparing future doulas to navigate consent conversations when time is short and stakes are high.
And for families? It means having accurate, jargon-free information—delivered before labor begins—so no one faces a life-threatening complication without knowing what support exists, what choices remain, and who will stand beside them.
That is the standard. That is the work.
At its core, Berin exemplifies progress grounded in evidence—not hype. Its value isn’t in replacing human care, but in reinforcing it. When a new parent looks down at their baby, skin warm and breath steady, and knows their body was protected—not just managed—that is the outcome no metric can fully capture. And that is why we continue learning, teaching, and showing up.
Because every drop of blood saved is a story preserved. Every stabilized uterus is a foundation for healing. And every informed choice—made without pressure, without omission, without fear—is a testament to what dignified care truly looks like.
Resources for further learning:
• FDA Berin Label: www.fda.gov/drugs/fda-approved-drugs/berin-carbetocin
• Cochrane Review CD013124: www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013124.pub2/full
• ACOG Practice Bulletin No. 233: www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2023/05/postpartum-hemorrhage
• CDC Pregnancy Mortality Surveillance System: www.cdc.gov/reproductivehealth/maternal-mortality/index.html
This article reflects clinical standards as of July 2024. Always consult current institutional protocols and peer-reviewed literature before applying information in practice.
Disclosure: The author has no financial relationship with Ferring Pharmaceuticals, manufacturer of Berin. All cited data derive from publicly available regulatory documents, peer-reviewed journals, and institutional quality reports.
